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Structured Abstract  
Aims: Coronary guidewire-based diagnostic assessments with hyperemia may 
cause iatrogenic complications. We assessed the safety of guidewire-based 
measurement of coronary physiology using intravenous adenosine in patients with 
an acute coronary syndrome. 
Methods: We prospectively enrolled invasively managed STEMI and NSTEMI 
patients in two simultaneously conducted studies in 6 centers (NCT01764334; 
NCT02072850). All of the participants underwent a diagnostic coronary guidewire 
study using intravenous adenosine (140 g/kg/min) infusion for 1 - 2 minutes. The 
patients were prospectively assessed for the occurrence of serious adverse events 
(SAE) and symptoms and invasively measured hemodynamics were also recorded. 
Results: 648 patients (n=298 STEMI patients in 1 hospital; mean time to reperfusion 
253 min; n=350 NSTEMI in 6 hospitals; median time to angiography from index chest 
pain episode 3 (2, 5) days) were included between March 2011 to May 2013. Two 
NSTEMI patients (0.03% overall) experienced a coronary dissection related to the 
guidewire. No guidewire dissections occurred in the STEMI patients. Chest 
symptoms were reported in the majority (86%) of patient’s symptoms during the 
adenosine infusion. No serious adverse events occurred during infusion of 
adenosine and all of the symptoms resolved after the infusion ceased.  
Conclusions: In this multicenter analysis, guidewire-based measurement of FFR 
and IMR using intravenous adenosine was safe in patients following STEMI or 
NSTEMI. Self-limiting symptoms were common but not associated with serious 
adverse events. Finally, coronary dissection in STEMI and NSTEMI patients was 
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Introduction 
Coronary guidewire-based sensors can be used in the cardiac catheterization 
laboratory to provide functional information on coronary artery disease severity and 
microvascular function. The myocardial fractional flow reserve (FFR) assesses the 
physiological significance of a coronary stenosis and is expressed as the ratio of 
maximal blood flow in a stenotic artery to maximal flow if theoretically the artery was 
unobstructed. FFR-guided management is evidence-based in patients with stable 
coronary artery disease (DEFER [1], FAME [2], FAME-2 [3]) and has emerging 
clinical utility for measurement of non-infarct artery disease in patients with recent or 
acute myocardial infarction (MI) [4][5]. The index of microvascular resistance (IMR) 
measured in the culprit coronary artery has prognostic importance in patients with 
acute ST-elevation myocardial infarction (STEMI) [6][7]. However since FFR and 
IMR measurement involves pharmacological hyperemia and guidewire 
instrumentation, there are theoretical risks of serious adverse events (SAE) including 
ventricular arrhythmias with intravenous adenosine and coronary dissection (both 
~0.5% incidence) [8]. 
Intravenous adenosine induces hyperemia through interactions with A2A receptors. 
However, due to the ubiquitious expression of adenosine receptors, adenosine is 
also associated with unwanted off-target side-effects. For example, interaction with 
bronchial A2B receptors can lead to mast cell degranulation and bronchoconstriction 
[9]. Furthermore, activation of cardiac A1 receptors has a myocardial depressant 
effect with negative chronotropic and dromotropic effects [10]. It is these unwanted 
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of hyperemia or develop non hyperemic indices of stenosis assessment in the 
catheter laboratory [11] [12]. 
Intracoronary adenosine may also be used therapeutically for the treatment of no-
reflow in STEMI [13, 14], and the role of FFR-guided PCI in STEMI patients with 
multivessel coronary disease [15] is currently being evaluated in the COMPARE-
ACUTE (NCT01399736), COMPLETE (NCT01740479) and PRIMULTI 
(NCT01960933) clinical trials. 
In November 2013 the United States (US) Food and Drug Administration (FDA) 
issued a safety announcement on the risk of myocardial infarction (MI) and death in 
patients receiving Adenoscan (adenosine) for stress testing [16] (Supplementary 
File). This announcement followed from reports in the FDA Adverse Event Reporting 
System (FAERS) and medical literature of serious adverse events (SAE) from 1995 
to 2013, including 6 cases of MI and 27 cases of death following adenosine 
administration (typically within 6 hours) [16].  
We aimed to prospectively assess the safety of guidewire based measurement of 
coronary physiology using intravenous adenosine amongst patients with acute or 
recent myocardial infarction (MI). Based on our prior experience with intravenous 
adenosine in this setting [6] [7] [17] [18], we hypothesized that intravenous 
















We simultaneously conducted two prospective studies involving assessments of 
coronary physiology in patients with acute or recent MI.   The first was a study of the 
natural history of coronary microvascular function in patients with acute STEMI 
undergoing emergency PCI (the BHF MR-MI study, NCT02072850) [20]. Two 
hundred and ninety-eight STEMI patients were enrolled acutely and had IMR 
measured invasively in the culprit coronary artery with a diagnostic coronary 
guidewire (PressureWire Certus, St Jude Medical) during primary or rescue PCI. 
The protocol did not involve FFR or IMR measurements in the non-infarct arteries. 
The enrolment period was March 2011 - November 2012. Patients diagnosed with 
an acute STEMI [21] and who were undergoing primary or rescue PCI were eligible 
to participate. In the second study, three hundred and fifty NSTEMI patients were 
enrolled in the BHF FAMOUS-NSTEMI study (NCT01764334) [4] [5]. Six hospitals in 
the United Kingdom participated (3 academic and 3 non-academic regional 
hospitals). The patients in this study underwent urgent invasive management and 
had an FFR measurement in one or more coronary arteries with at least a single 
coronary stenosis ≥ 30% severity of the reference vessel diameter by visual 
assessment. The patients with NSTEMI were enrolled during urgent care and the 
median time to invasive angiography was 3 days (Table 1) [5].  
The exclusion criteria for administration of intravenous adenosine included evidence 
of 2nd or 3rd degree heart block on the ECG, long QT syndrome, cardiogenic shock, 
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criteria for both studies are provided in Supplementary Tables 1 and 2. The study 
was approved by the UK National Research Ethics Service and all participants 
provided written informed consent.  
Catheter laboratory management 
The clinical and catheter laboratory management followed contemporary guidelines 
for STEMI [21] and NSTEMI [21] [23].  
Measurement of FFR and IMR  
In patients with STEMI, infarct artery microvascular function (IMR) was measured at 
the end of the primary or rescue PCI (Figure 1). Thus we initially opted for a 
conventional workhorse wire whilst using a pressure wire at the end of the 
procedure. In patients with NSTEMI, FFR (and IMR) was measured at the beginning 
of the diagnostic procedure in all participants. Additionally, the pressure wire was 
used to perform PCI in most NSTEMI patients. FFR and IMR were measured using a 
temperature and pressure sensitive guide wire (PressureWire Certus St Jude 
Medical, Uppsala, Sweden). The guidewire was calibrated outside the body, 
equalized with aortic pressure at the ostium of the guide catheter, and then 
advanced to the distal third of the culprit artery [6] [7] [17] [18]. Intracoronary nitrate 
(200 µg) was administered to minimise coronary artery tone and maintain coronary 
volume. Intravenous adenosine was administered at a rate of 140 µg/kg/min via a 
large peripheral vein for 1 - 2 minutes (Supplementary Table 3).  
The patient's response to adenosine administration was a pre-defined safety 
outcome [20]. Aortic and distal coronary pressures were recorded invasively before 
and during adenosine administration. In addition, patients’ symptoms and heart rate 
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proforma. All SAEs in study participants were prospectively documented by clinical 
and research staff after the patient was enrolled in the study in line with the trial 
protocol. All adverse events were recorded in the clinical report form (CRF). SAEs 
were notified to the Sponsor of the studies for pharmacovigilance and assessed, 
reported, analysed and managed in accordance with the Medicines for Human Use 
(Clinical Trials) Regulations 2004 (as amended) [24].  
An SAE was defined as an event that results in death, is life threatening, requires 
hospitalisation or prolongation of existing hospitalisation, results in persistent or 
significant disability or incapacity, or is otherwise considered medically significant by 
the investigator. 
Major adverse cardiac events (MACE), were defined as the occurrence of death, 
myocardial infarction, or hospitalization for heart failure [25]. In the STEMI study, 
source data for all of the SAE and MACE were assessed by a cardiologist (A.M.) 
who was independent of the research team. This cardiologist was blinded to all of 
the other clinical data [20]. In the NSTEMI study, source clinical data for all SAE of 
suspected cardiovascular origin and all deaths were reviewed by an independent 
clinical event committee blinded to treatment group assignment (FFR-guided group 
or angiography guided group) [4][5]. The CEC also assessed the angiograms of SAE 
attributed to procedure-related complications. 
Statistics 
Continuous data with a normal distribution were summarized with the mean ± 
standard deviation (SD). Paired t-tests were used to assess hemodynamic data 
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0.05. The statistical analyses were performed using the SPSS statistical software 
package 14.0 for Windows (SPSS Inc., Chicago, IL, USA).  
Results  
Baseline characteristics  
648 patients (n=298 patients with STEMI in 1 hospital; n=350 patients with NSTEMI 
in 6 hospitals) were included between March 2011 - May 2013. Their clinical 
characteristics are presented in Table 1.  
In the patients with STEMI, evidence of hemodynamic instability on arrival in the 
cardiac catheter laboratory was common. Thirty-three (11.1%) patients had a systolic 
blood pressure (BP) of < 90 mmHg, 20 (7.2%) patients had ventricular fibrillation 
(VF) or ventricular tachycardia (VT) before or during PCI but prior to adenosine 
administration, and 4 (1.4%) patients received intra-aortic balloon pump (IABP) 
counterpulsation therapy during the PCI. In the patients with NSTEMI there were no 
patients with VF/VT during the procedure and only 1 (0.3%) patient required IABP. 
Symptoms and adverse events  
During adenosine infusion, 255 (85.6%) STEMI patients reported symptoms 
including chest discomfort, dyspnea and facial flushing, all of which resolved 
immediately after the infusion ceased. There were no other symptoms reported. No 
MACE or atrial or ventricular arrhythmias occurred in association with intravenous 
adenosine administration. There were no SAEs related to adenosine.  
In the STEMI cohort, MACE occurred in 3 (1.0%) patients within 24 hours of the PCI. 
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the distal end of the stent; one patient with severe left ventricular dysfunction 
experienced ventricular fibrillation in the coronary care unit; one patient died 
suddenly from myocardial rupture that was confirmed at autopsy. All of these events 
occurred in the coronary care unit and none of these events were temporally 
associated with the adenosine infusion in the catheter laboratory. In the STEMI 
cohort there were no pressure-wire related dissections and no SAE related to 
arrhythmias. 
In the NSTEMI cohort, no MACE occurred in association with the adenosine infusion. 
There were 2 (0.6%) cases of coronary dissection related to the guidewire. There 
were 4 cases of in-hospital adverse events, including 3 (0.9%) cases of contrast 
nephropathy and 3 (0.9%) cases of major bleeding but none related to adenosine 
infusion. There were no SAE related to bradyarrhythmias or tachyarrythmias and 
FFR was measured in all subjects. 
Hemodynamic changes 
All Patients 
In 330 patients with complete hemodynamic data (n=186 STEMI, n=144 NSTEMI), 
aortic systolic blood pressure was reduced during adenosine administration (systolic 
BP (rest vs. adenosine): 124.5 (26.0) mmHg vs. 111.7 (24.7) mmHg, (n=330) [95% 
CI 12.8 (11.3, 14.3) p<0.001] as was diastolic BP (67.0 (12.8) mmHg vs. 60.5 (13.2) 
mmHg (n=330) [95% CI 6.5 (5.6, 7.4) p<0.001]. Heart rate increased to 64.7 (13.0) 
bpm from 58.3 (12.1) bpm,) [95% CI 6.3 (5.6, 7.1) p<0.001]. The proximal aortic 
pressure (Pa) was also reduced during adenosine administration (systolic BP (rest 
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(13.9, 17.0) p<0.001] as was the distal coronary pressure (64.7 (14.4) mmHg vs. 
55.2 (14.4) mmHg [95% CI 9.4 (8.5, 10.4) p<0.001]. 
STEMI  
In the STEMI cohort (n=298), non-invasive hemodynamic data (blood pressure and 
heart rate) were available for all study participants (Table 2). Complete aortic 
hemodynamic data before and during adenosine infusion were available in 186 
STEMI patients with distal coronary (Pd) hemodynamic data recorded in 258 STEMI 
patients (Table 3). The mean (SD) aortic systolic BP fell from 120.0 (22.6) mmHg at 
baseline to 106.5 (21.3) mmHg during adenosine infusion [95% CI 13.5 (11.6, 15.5) 
p<0.001]. Aortic diastolic BP was also reduced by adenosine infusion (67.9 (13.5) 
mmHg vs. 61.0 (13.6) mmHg [95% CI 7.0 (5.8, 8.1) p<0.001] whereas heart rate 
increased from 63.2 (12.1) bpm at rest to 69.8 (12.5) bpm [95% CI 6.6 (5.6, 7.6) 
p<0.001]. Compared to patients who did not experience symptoms with adenosine, 
patients who did experience symptoms had a greater rise in heart rate, but BP 
changes were similar (Table 4). 
NSTEMI 
In the NSTEMI cohort (n=350), complete aortic hemodynamic data were available for 
144 NSTEMI patients with distal coronary (Pd) hemodynamic data recorded in 165 
NSTEMI patients. The mean (SD) non-invasive aortic systolic BP reduced from 
130.3 (28.8) mmHg under resting conditions to 118.5 (27.0) mmHg during adenosine 
infusion [95% CI 11.8 (9.4, 14.2) p<0.001]. Aortic diastolic BP was also reduced by 
adenosine infusion (65.9 (11.9) mmHg vs. 60.0 (12.7) mmHg [95% CI 5.9 (4.5, 7.2) 
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Discussion 
We report the largest study to date of guidewire-based measurements of FFR and/or 
IMR in patients with acute coronary syndromes. Our study is the first to report 
information on a pre-specified outcome relating to the safety of intravenous 
adenosine in patients with an acute STEMI or recent NSTEMI, who were 
prospectively enrolled simultaneously in parallel studies. The main findings of our 
multicenter study are that, first, coronary dissection due to the guidewire was rare 
(≤0.03%). Second, brief intravenous adenosine infusion in MI patients for diagnostic 
purposes was commonly associated with symptoms but these symptoms were brief 
and self-limiting and were not associated with any SAEs; most importantly, the use 
of adenosine was safe and not associated with any SAEs during routine emergency 
care.  
Only 2 guidewire-related coronary dissections occurred in 698 prospectively enrolled 
MI patients undergoing emergency or urgent invasive management. This result 
represents evidence for the safety of guidewire-based assessments of coronary 
physiology. Guidewire dissections were less common than in previous studies [e.g. 
RIPCORD (1.5%)] [8]. We believe that the timing of the pressure wire study within 
the procedure partially explains the difference in the dissection rates. In the patients 
with acute STEMI, pressure wire instrumentation in the infarct-artery post-PCI was 
not associated with any complications. In the patients with recent NSTEMI, the 2 
guidewire dissections occurred during diagnostic procedures before stent 
implantation. In the 350 NSTEMI participants in this trial, 706 lesions (≥ 30% lumen 
narrowing) were reported and FFR data were obtained in 704 (>99%) of these 
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Despite this, the incidence of guidewire dissections in the NSTEMI patients was very 
low and this experience is evidence of safety in the hands of trained cardiologists.  
In our study, predictable symptoms associated with intravenous adenosine occurred 
in the majority of patients and can be explained by the pharmacological effects of 
this naturally occurring vasodilator [25]. However, since the half life of adenosine is < 
10 seconds, these symptoms were extremely short-lived [26]. Patients who 
experienced symptoms had a slightly higher increase in heart rate. A minority of 
patients (14%) did not experience symptoms with adenosine infusion. This may be 
explained by the presence of concurrent chest symptoms associated with myocardial 
infarction and also treatment with sedative and opiate therapies. There were no 
serious adverse events associated with intravenous adenosine. None of the patients 
experienced sustained atrial or ventricular tachyarrhythmia. Overall, the reported 
symptoms that were observed in these cohorts were typical of what might be 
expected with intravenous adenosine. Based on the evidence of safety in this study, 
we think that when a clinician plans to administer intravenous adenosine, the patient 
should be advised that symptoms are likely but self-limiting and not associated with 
any other consequences. Adverse events, such as atrial and ventricular fibrillation, 
are rare [8] and, in fact, no such events occurred in the 648 MI patients in this 
analysis. 
Systolic and diastolic blood pressures were reduced with intravenous adenosine 
consistent with an A2A receptor-mediated response. However, a rise in heart rate of 
>10% or a fall in systolic BP >10% occurred in less than half of the STEMI and 
NSTEMI patients in our study. These observations could be explained by the fact 
that the patients already had tachycardia due to STEMI, and they had been treated 
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response (e.g. intravenous morphine). It is also possible that there was an 
attenuated sympathetic response due to beta blocker treatment.  
Of the 6 hospitals in the FAMOUS-NSTEMI trial [4] [5], 3 were regional non-
academic centers without a track record in coronary physiology research. The 
multicenter design was intended to make the results of this trial more representative 
of routine care, relevant to “real world” practice and novel. 
In STEMI patients, guidewire-based measurement of coronary microvascular 
function with intravenous adenosine is mainly used in clinical research studies (as 
was the case here in the STEMI group). IMR in the infarct-related artery has 
prognostic value when measured invasively at the end of primary PCI [6] [7] [17] 
[18], and IMR has potential utility for stratification of higher risk patients for more 
intensive management after primary PCI [6] [18]. Moreover, potential diagnostic 
applications are emerging for FFR to inform the acute treatment decisions for 
patients with non-infarct artery disease [5]. Intracoronary adenosine is used to treat 
no-reflow [13, 14] and FFR-guided PCI in STEMI patients with multivessel coronary 
disease [15], is currently being evaluated in the COMPARE-ACUTE 
(NCT01399736), COMPLETE (NCT01740479) and PRIMULTI (NCT01960933) 
trials.  
In our study invasive measurements of FFR and IMR can be safely obtained in 
patients with acute or recent MI. IMR has been shown to be a biomarker of severe 
microvascular injury and has prognostic value in identifying the highest risk patients 
at an early stage, potentially enabling triage of higher risk patients to intensification 
of therapy. FFR measurement in the acute setting, especially in non-culprit disease, 
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Adenosine is an established drug for use in pharmacological stress testing. 
Adenoscan has been marketed from 18 May 1995. From this date until 10 April 10 
2013 the FAERS database accrued 26 reports of myocardial infarction (MI) and 29 
deaths with regadenoson and 6 reports of myocardial infarction and 27 deaths 
reported with Adenoscan. There were two case reports of MI associated with 
Lexiscan administration but none with Adenoscan [27] [28] and the incidence of 
cardiovascular adverse events associated with these drugs is similarly uncommon 
[29-33]. In light of these post-marketing reports the FDA recommended to "Avoid 
using these drugs (Lexiscan or Adenoscan) in patients with signs or symptoms of 
unstable angina or cardiovascular instability, as these patients may be at greater risk 
for serious cardiovascular adverse reactions" [16]. The FDA warning was directed to 
office-based administration of intravenous adenosine, and this environment contrasts 
with the cardiac catheterization laboratory where medical support is immediately 
available to treat patients with iatrogenic complications. Our results also provide 
reassurance for the use of intravenous adenosine in the catheter laboratory setting. 
In contrast to the FDA recommendations, our findings are supported by the results 
from similar studies in other centers, in which intravenous adenosine has been used 
in patients with acute MI [7, 34-37] [35]. Moreover, a meta-analysis evaluating the 
safety and efficacy of intracoronary adenosine in 460 patients with STEMI 
undergoing PCI found no difference in the safety endpoints of bradycardia, 
ventricular arrhythmia and chest pain compared with placebo [38]. Our study is 
different, since the safety of diagnostic guidewire instrumentation and systemic 
administration of adenosine (rather than intracoronary adenosine) were prospectively 
assessed in NSTEMI and STEMI patients. Another study, using a similar protocol for 
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of clinically significant bradycardia [39]. In our hands, adenosine was not associated 
with any SAE when administered to reperfused patients with STEMI at the end of 
emergency PCI for a short period of time (1-2 minutes) and the absence of SAE in 
the NSTEMI patients provides further evidence of safety. 
Limitations 
Our study has several limitations. First, we do not have information on other 
hyperemic drugs, such as regadenoson. Second, although safety assessments were 
performed and recorded in all of the patients at the time of the procedure, symptom 
reporting was incomplete. The available results confirm that symptoms typically 
occur with intravenous adenosine. Third, complete hemodynamic recordings were 
not available in all of the participants because resting arterial pressure is not required 
for IMR. Fourth, pressure wire studies were restricted to the infarct-related artery 
rather than the non-infarct artery in the STEMI cohort study. Nonetheless, we 
provide comprehensive hemodynamic data and information on symptoms from 
prospective evaluations in individual patients who were enrolled in studies that had 
been designed with an open approach to enrolment of ‘all-comers’. We think our 
observations are representative of ‘real-world’ clinical practice.  
Conclusion 
Guidewire-based measurement of coronary microvascular function involving 
intravenous adenosine infusion was feasible and safe during emergency or urgent 
PCI for STEMI and NSTEMI. The symptoms related to adenosine were predictable, 
self-limiting and not associated with adverse events. Finally, coronary dissection in 
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A hemodynamic recording obtained from a diagnostic pressure- and temperature-
sensitive guidewire (PressureWire Certus, St. Jude Medical, Mn.) located in a 
culprit coronary artery at the end of primary PCI. 
The blue arrow represents the thermodilution recordings during resting conditions 
before adenosine administration. The thermodilution curve represents the transit 
time for the change in temperature detected by the distal guidewire thermistor 
following intra-coronary bolus injection of saline (room temperature) via the guiding 
catheter. The subsequent yellow arrow represents the transit times for thermodilution 
curves following intra-coronary injections of saline during hyperemia with adenosine 
(140 µg/kg/min). During hyperemia, there is evidence of a reduction in arterial blood 
pressure depicted by the yellow arrow, reflecting the typical hemodynamic response 
in the systemic and coronary circulations to intravenous adenosine.  
Hemodynamic recordings were assessed with vendor software (RADIView Version 
2.2, St Jude Medical, Mn.). The systolic blood pressure and diastolic blood pressure 
during at least 3 cardiac cycles in steady-state conditions at rest and during 
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Table 1. Clinical characteristics of the study participants on admission. 




Clinical    
Age, years  59.4 62.0 
Male sex, n (%)  216 (72)  260 (74) 
BMI, (kg/m2)  28.7  29 (5) 
History    
Hypertension, n (%)  95 (32) 159 (45)  
Current smoking, n (%)  184 (62) 143 (41) 
Hypercholesterolemia, n (%)  81 (27) 127 (36) 
Diabetes mellitus‡, n (%)  32 (11) 52 (15) 
Previous myocardial infarction, n (%)  20 (7) 46 (13) 
Previous PCI, n (%)  16 (5) 38 (11) 
Presenting characteristics    
Heart rate, bpm  80 (44) 74 (16) 
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Diastolic blood pressure, mmHg  79 (14) 81 (17) 
Time from symptom onset to reperfusion, 
min 
 253 - 
Time from index episode of myocardial 
ischemia to invasive angiogram, days 
 - 3 (2, 5) 
Ventricular tachycardia or fibrillation†, n 
(%) 
 20 (7) 0 (0) 
Heart failure, Killip class at presentation, 
n (%) 
I 212 (71) 308 (88) 
 II 64 (22) 33 (9) 
 III 16 (5) 5 (2) 
 IV 6 (2) 4 (1) 
Coronary angiography    
Reperfusion strategy, n (%)    
Primary PCI   275 (92) - 
Rescue PCI (failed thrombolysis)  23 (8) - 
Adjunctive Therapy During PCI    
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Clopidogrel (600mg) (%)  297 (99) 337 (96) 
Heparin (%)  298 (100) 333 (95) 
Anti-GP IIb/IIIa (%)  273 (92) 79 (26) 
Number of diseased arteries¥, n (%) 0 0 (0) 10 (3) 
 1 165 (55) 130 (37) 
 2 95 (32) 141 (40) 
 3 38 (13) 60 (17) 
 4 0 (0) 9 (3) 
Culprit artery, n (%) LMS 0 (0) 2 (1) 
 LAD 110 (37) 152 (43) 
 LCX 55 (18) 106 (30) 
 RCA 133 (45) 90 (26) 
TIMI coronary flow grade pre-PCI, n (%) 0/1 214 (72) - 
 2 56  (19) - 
 3 28  (9) - 
TIMI coronary flow grade post-PCI, n (%) 0/1 2 (1) 33 (9) 
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 3 282 (94) 289 (83) 
Abbreviations – Body mass index (BMI), percutaneous coronary intervention (PCI), 
beats per minute (bpm), thrombolysis in myocardial infarction (TIMI), left main stem 
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Table 2. Blood pressure and heart rate at the start and end of emergency PCI in 298 
STEMI subjects. 
Parameter  PCI start PCI end Mean Change (CI) P value 






0.6 ( -4.3, 5.6) 0.800 






14.0 (11.6, 16.4) <0.001 






7.0 (5.6, 8.5) <0.001 
Abbreviations – Heart Rate (HR), Blood Pressure (BP), Standard Deviation (SD), 
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Table 3. Coronary (Pd) systolic and diastolic blood pressure recorded in 258 STEMI 
subjects. 
Blood Pressure (BP) Rest  Adenosine  Mean Change (CI) P value 






15.8 (14.1, 17.5)  <0.001 






9.4 (8.4, 10.3) <0.001 
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Table 4. Blood pressure and heart rate of STEMI patients with symptoms recorded 









Mean (SD) systolic change, 
mmHg 
-14.2 (13.5) -10.5 (13.5) -3.6 (-8.3, 1.5) 0.167 
Mean (SD) diastolic change, 
mmHg 
-7.2 (7.8) -6.0 (8.4) -1.2 (-4.2, 1.9) 0.451 
Mean (SD) HR change, bpm 7.1 (7.0) 4.0 (6.2)* 3.1 (0.5, 5.7) 0.020 













  37 
 
Table 5. Distal coronary (Pd) artery blood pressure recorded in 165 NSTEMI 
subjects. 
Blood Pressure (BP) Rest  Adenosine  Mean Change (CI) P value 






15.3 (13.0, 17.7) <0.001 






10.0 (8.4, 11.5) <0.001 
Abbreviations – Blood Pressure (BP), Standard Deviation (SD) *p<0.001 vs. baseline 
(paired t-test) 
